Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arthritis Care Res (Hoboken)
Glavni autori: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Spondyloarthritis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://ncbi.nlm.nih.gov/pubmed/27696727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23092
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items